Celgene Flexes Its Muscles

In five short years, Celgene has used the cash from the blockbuster success of its flagship product Revlimid to pursue a wide range of deals for revenues now and new markets later. Its homegrown R&D has created a bountiful late-stage pipeline. It’s projecting even more Revlimid success in the next few years. So why aren’t investors buying?

Alex Lash

The circle of biotech companies that have grown into independent powerhouses is small and, with the sale of Genzyme...

More from Archive

More from In Vivo